| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| Other Sizes |
| ADME/Pharmacokinetics |
Metabolism / Metabolites
L-cysteine is a core compound in human sulfur metabolism. In proteins, the formation of disulfide bonds between cysteine sulfhydryl groups plays a crucial role in protein tertiary structure and enzyme activity; however, cysteine is always incorporated into polypeptide chains in its cysteine form. L-cysteine is degraded to pyruvate in two steps: desulfurization and transamination. Cysteine can be metabolized to taurine and carbon dioxide via the cysteine sulfinate pathway, the first step of which is the oxidation of cysteine to cysteine sulfinate. This step is catalyzed by cysteine dioxygenase. Cysteine sulfinate can be decarboxylated to taurine, or metabolized to pyruvate and sulfite via the putative intermediate β-sulfinylpyruvate, ultimately producing carbon dioxide and sulfate. Amino acid catabolism is essential for regulating the size of the free amino acid pool and participates in energy production and nutrient reuse. The carbon skeleton is typically converted into precursors or intermediates of the tricarboxylic acid cycle. For cysteine, the reduced sulfur derived from the thiol group must also be oxidized to prevent its accumulation to toxic concentrations. This article introduces a mitochondrial sulfur catabolism pathway that catalyzes the complete oxidation of L-cysteine to pyruvate and thiosulfate. After L-cysteine is transaminated to 3-mercaptopyruvate, its thiol group is transferred to glutathione via thiotransferase 1 and oxidized to sulfite by the sulfur dioxygenase ETHE1. Subsequently, thiotransferase 1 adds a second persulfate group, converting the sulfite to thiosulfate. This pathway is most important in early embryonic development and vegetative growth under light-limited conditions. Characterization of double mutants generated from Arabidopsis thaliana ETHE1 and thiotransferase 1 T-DNA insert lines revealed that intermediates in the ETHE1-dependent pathway (likely persulfates) interfere with amino acid catabolism and induce early senescence. Uremic toxins often accumulate in the blood due to overeating or poor renal filtration. Most uremic toxins are metabolic waste products, usually excreted in urine or feces. |
|---|---|
| Additional Infomation |
L-cysteine is an optically active cysteine with an L-configuration. It is used as a flour treatment agent, a human metabolite, and an inhibitor of EC 4.3.1.3 (histidine ammonia-lyase). It is a serine family amino acid, a protein-synthesizing amino acid, cysteine, and an L-α-amino acid. It is the conjugate base of L-cysteine. It is the conjugate acid of L-cysteine (1-). It is the enantiomer of D-cysteine. It is the zwitterion tautomer of L-cysteine. Cysteine is a thiol-containing non-essential amino acid that can be oxidized to cystine. L-cysteine is a metabolite found or produced in Escherichia coli (K12 strain, MG1655 strain). Cysteine has also been reported in Indigofera tinctoria, pomegranate, and other organisms with relevant data. Cysteine is an essential sulfur-containing amino acid for humans and is associated with cystine. Cysteine is crucial for protein synthesis, detoxification, and various metabolic functions. Cysteine is found in β-keratin, a major protein in nails, skin, and hair. Cysteine is crucial for collagen production and the elasticity and texture of the skin. It is also an essential amino acid for the synthesis of taurine, a component of the antioxidant glutathione, and plays a role in the metabolism of important biochemicals such as coenzyme A, heparin, and biotin. (NCI04)
Cysteine is a uremic toxin. Based on their chemical and physical properties, uremic toxins can be classified into three main categories: 1) small molecule, water-soluble, non-protein-bound compounds, such as urea; 2) small molecule, lipid-soluble, and/or protein-bound compounds, such as phenols; 3) larger so-called medium molecules, such as β2-microglobulin. Long-term exposure to uremic toxins can lead to various diseases, including kidney damage, chronic kidney disease, and cardiovascular disease. Cysteine is a naturally occurring sulfur-containing amino acid found in most proteins, but in small amounts. Among the 20 naturally occurring amino acids, cysteine is unique in that it contains a sulfhydryl group. The thiol group can undergo redox reactions; cysteine, when oxidized, can form cystine, which is composed of two cysteine residues linked by a disulfide bond. This reaction is reversible: reducing the disulfide bond regenerates two cysteine molecules. The disulfide bond of cystine is crucial for the structure of many proteins. Cysteine commonly participates in electron transfer reactions and helps enzymes catalyze reactions. Cysteine is also a component of the antioxidant glutathione. N-acetyl-L-cysteine (NAC) is a form of cysteine in which the acetyl group is attached to the nitrogen atom of cysteine and is sold as a dietary supplement. The name cysteine comes from the Greek word kustis, meaning bladder—cysteine was originally isolated from kidney stones. Because cysteine contains a thiol group, it can undergo redox reactions. Oxidation of cysteine can form disulfide bonds with other thiols or be further oxidized to produce sulfinic acids or sulfonic acids. The thiol group of cysteine is also nucleophilic and can undergo addition and substitution reactions. Thiol groups exhibit significantly enhanced reactivity upon ionization. Cysteine residues in proteins have near-neutral pKa values, thus they typically exist intracellularly as reactive thiolates. Thiol groups have a high affinity for heavy metals, allowing cysteine-containing proteins to bind tightly to metals such as mercury, lead, and cadmium. Cysteine possesses antioxidant properties due to its redox capabilities. Cysteine is an important source of sulfur in human metabolism. Although classified as a non-essential amino acid, it may be essential for infants, the elderly, and individuals with certain metabolic disorders or malabsorption syndromes. In the future, cysteine may be recognized as an essential or conditionally essential amino acid. Cysteine plays a crucial role in energy metabolism. It exists in the form of cystine and is a structural component of many tissues and hormones. Cysteine has a wide range of clinical applications, from treating hair loss and psoriasis to preventing smoking-induced coughs. In some cases, oral cysteine therapy has proven highly effective in treating asthma and can help patients discontinue theophylline and other medications. In addition, cysteine can enhance the effectiveness of topical silver, tin, and zinc salts in preventing tooth decay. In the future, cysteine may play a role in treating cobalt poisoning, diabetes, mental illness, cancer, and epilepsy. Cysteine is a thiol-containing non-essential amino acid that oxidizes to form cystine. See also: Cysteine hydrochloride (salt form)... See more... Drug Indications For the prevention of liver and kidney damage caused by acetaminophen overdose Mechanism of Action Under normal physiological conditions, the human body can usually synthesize cysteine if methionine is sufficient. Cysteine is usually synthesized in the body when methionine is sufficient. Cysteine has antioxidant properties and participates in redox reactions. The antioxidant properties of cysteine are usually manifested in the tripeptide glutathione, which is present in the human body and other organisms. Due to the limited bioavailability of glutathione (GSH) in the body, it usually needs to be biosynthesized from its constituent amino acids—cysteine, glycine, and glutamate. Glutamic acid and glycine are abundant in the diets of most industrialized countries, but cysteine supply may be a limiting substrate. In human metabolism, cysteine participates as a precursor in the formation of iron-sulfur clusters and sulfides in nitrogenase. In a 1994 report by five top cigarette companies, cysteine was listed as one of 599 additives in cigarettes. However, like most cigarette additives, its use or purpose remains unclear. Adding cysteine to cigarettes may offer two benefits: firstly, as an expectorant, since smoking increases the production of mucus in the lungs; and secondly, by increasing the beneficial antioxidant glutathione (which is lower in smokers). |
| Molecular Formula |
C3H7NO2S
|
|---|---|
| Molecular Weight |
121.15
|
| Exact Mass |
121.019
|
| CAS # |
52-90-4
|
| Related CAS # |
62488-11-3;7048-04-6 (Hydrochloride)
|
| PubChem CID |
5862
|
| Appearance |
Colorless crystals
White crystals |
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
293.9±35.0 °C at 760 mmHg
|
| Melting Point |
220 °C (dec.)(lit.)
|
| Flash Point |
131.5±25.9 °C
|
| Vapour Pressure |
0.0±1.3 mmHg at 25°C
|
| Index of Refraction |
1.550
|
| LogP |
0.23
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
7
|
| Complexity |
75.3
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
S([H])C([H])([H])[C@@]([H])(C(=O)O[H])N([H])[H]
|
| InChi Key |
XUJNEKJLAYXESH-REOHCLBHSA-N
|
| InChi Code |
InChI=1S/C3H7NO2S/c4-2(1-7)3(5)6/h2,7H,1,4H2,(H,5,6)/t2-/m0/s1
|
| Chemical Name |
(2R)-2-amino-3-sulfanylpropanoic acid
|
| Synonyms |
Cysteinum; FEMA No. 3263; Cysteine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 8.2542 mL | 41.2712 mL | 82.5423 mL | |
| 5 mM | 1.6508 mL | 8.2542 mL | 16.5085 mL | |
| 10 mM | 0.8254 mL | 4.1271 mL | 8.2542 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT05485558 | Recruiting | Drug: N-acetyl cysteine Drug: Placebo |
Drug Resistant Epilepsy | Tanta University | September 15, 2022 | Phase 2 |
| NCT02252341 | Unknown | Dietary Supplement: N- Acetyl-Cysteine |
Bipolar Disorder | Universidade Estadual de Maringá |
September 2014 | Phase 4 |
| NCT03032601 | Enrolling by invitation | Dietary Supplement: N- acetyl Cysteine |
Multiple Sclerosis | Thomas Jefferson University | January 5, 2017 | Not Applicable |
| NCT05122559 | Recruiting | Drug: N-acetyl cysteine Drug: Placebo |
Multiple Sclerosis | Emmanuelle Waubant, MD PhD |
February 16, 2022 | Phase 2 |
| NCT06202911 | Active, not recruiting | Drug: oral n-acetyl cysteine | Oral N-acetyl Cysteine | Ain Shams University | January 1, 2023 | Phase 4 |
|
|
|